These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19903829)

  • 21. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
    Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
    J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
    Zhorov BS; Ananthanarayanan VS
    Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonequilibrium, multiple-timescale simulations of ligand-receptor interactions in structured protein systems.
    Zhang Y; Peters MH; Li Y
    Proteins; 2003 Aug; 52(3):339-48. PubMed ID: 12866048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolutionary identification of a subtype specific functional site in the ligand binding domain of steroid receptors.
    Raviscioni M; He Q; Salicru EM; Smith CL; Lichtarge O
    Proteins; 2006 Sep; 64(4):1046-57. PubMed ID: 16835908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.
    Ballesteros JA; Shi L; Javitch JA
    Mol Pharmacol; 2001 Jul; 60(1):1-19. PubMed ID: 11408595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of asymmetric binding in ligand-receptor systems with 1:2 interaction ratio.
    Míguez DG
    Biophys Chem; 2010 May; 148(1-3):74-81. PubMed ID: 20332059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LTHREADER: prediction of ligand-receptor interactions using localized threading.
    Pulim V; Bienkowska J; Berger B
    Pac Symp Biocomput; 2007; ():64-75. PubMed ID: 17992745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic beads method for determination of binding of drugs to melanin.
    Marszałł MP; Buciński A; Goryński K; Proszowska A; Kaliszan R
    J Chromatogr A; 2011 Jan; 1218(2):229-36. PubMed ID: 21144529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space.
    Rabal O; Oyarzabal J
    J Chem Inf Model; 2012 May; 52(5):1086-102. PubMed ID: 22486368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space.
    Cheng F; Li W; Wu Z; Wang X; Zhang C; Li J; Liu G; Tang Y
    J Chem Inf Model; 2013 Apr; 53(4):753-62. PubMed ID: 23527559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward an evolutionary containment of evolving pathogen-receptors by using an ensemble of multiple mutant ligands: from the viewpoint of fitness landscape in sequence space.
    Aita T; Husimi Y
    J Theor Biol; 2012 Mar; 296():49-55. PubMed ID: 22172531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of in-membrane receptor clustering upon binding of multivalent ligands.
    Grochmal A; Ferrero E; Milanesi L; Tomas S
    J Am Chem Soc; 2013 Jul; 135(27):10172-7. PubMed ID: 23763669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint modeling of clinical efficacy and safety with an application to diabetes studies.
    Zhao Y; Shen W; Fu H
    J Biopharm Stat; 2013; 23(5):1155-71. PubMed ID: 23957521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering selectivity and discrimination into ligand-receptor interfaces.
    Koh JT
    Chem Biol; 2002 Jan; 9(1):17-23. PubMed ID: 11841935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constituting a receptor-ligand information base from quality-enriched data.
    Hemm K; Aberer K; Hendlich M
    Proc Int Conf Intell Syst Mol Biol; 1995; 3():170-8. PubMed ID: 7584434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A new graphic method for determining the rate constant for affinity of a ligand for its receptor].
    Bobrovnik SA
    Ukr Biokhim Zh (1978); 1998; 70(6):144-6. PubMed ID: 10402664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling drug-melanin interaction with theoretical linear solvation energy relationships.
    Lowrey AH; Famini GR; Loumbev V; Wilson LY; Tosk JM
    Pigment Cell Res; 1997 Oct; 10(5):251-6. PubMed ID: 9359620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chemical kinetic model for ligand binding to identical and independent binding sites in vivo.
    Bond JP; Notides AC
    Anal Biochem; 1988 Nov; 175(1):238-51. PubMed ID: 2854373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of methods of identifying receptor binding models and analysis of parameters.
    Gurevich KG
    Theor Biol Med Model; 2004 Nov; 1():11. PubMed ID: 15546491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.